Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

被引：0

作者：

Eiji Oki

Yasunori Emi

Yuji Miyamoto

Akira Kabashima

Hidefumi Higashi

Yutaka Ogata

Masahiko Ikebe

Hiroshi Saeki

Shoji Tokunaga

Ken Shirabe

Toru Beppu

Shinji Uchida

Mitsuhisa Takatsuki

Masahiko Sakoda

Susumu Eguchi

Yoshito Akagi

Yoshihiro Kakeji

Hideo Baba

Shoji Natsugoe

Yoshihiko Maehara

机构：

[1] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences

[2] Saiseikai Fukuoka General Hospital,Department of Surgery

[3] Kumamoto University,Department of Gastroenterological Surgery, Graduate School of Medical Sciences

[4] Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers,Department of Surgery

[5] Steel Memorial Yawata Hospital,Department of Surgery

[6] Kurume University Medical Center,Department of Surgery

[7] Beppu Medical Center,Department of Gastroenterological Surgery

[8] Kyushu University Hospital,Medical Information Center

[9] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery

[10] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Digestive Surgery, Breast and Thyroid Surgery

[11] Kurume University School of Medicine,Department of Surgery

[12] Kobe University,Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine

来源：

Annals of Surgical Oncology | 2015年 / 22卷

关键词：

Bevacizumab; Oxaliplatin; Liver Resection; Capecitabine; Cetuximab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1067 / 1074

页数：7

共 161 条

[1]

Watanabe T(2012)Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer Int J Clin Oncol. 17 1-29

[2]

Itabashi M(1989)Resection of hepatic metastases from colorectal cancer. Biologic perspective Ann Surg. 210 127-138

[3]

Shimada Y(2013)Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases J Clin Oncol. 31 1931-1938

[4]

Tanaka S(1984)Treatment of metastatic disease of the liver: a skeptic’s view Semin Liver Dis. 4 170-179

[5]

Ito Y(2014)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol. 15 1065-1075

[6]

Ajioka Y(2014)Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy Crit Rev Oncol Hematol. 92 218-226

[7]

Steele G(2014)Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study) Ann Oncol. 25 1018-1025

[8]

Ravikumar TS(2009)The role of preoperative chemotherapy in patients with resectable colorectal liver metastases Ann Surg Oncol. 16 2385-2390

[9]

Ye LC(2013)A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases The METHEP trial. Ann Surg Oncol. 20 4289-4297

[10]

Liu TS(2013)FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) Ann Oncol. 24 2062-2067

← 1 2 3 4 5 6 7 8 9 10 →